Fed. Circ. Affirms Toss Of Hyptertension Treatment IP
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board ruling that invalidated a United Therapeutics Corp. patent for the drug Remodulin and other pulmonary arterial hypertension treatments after...To view the full article, register now.
Already a subscriber? Click here to view full article